Global Investor Engagement at RESI JPM 2026 Strengthens International Momentum

Brisbane, Australia – February 1, 2026 – Ketim Technologies participated in RESI JPM 2026 in San Francisco, engaging with global investors, strategic partners, and healthcare innovators during one of the world’s leading life sciences investment weeks.

Over several days, Dr. Clarissa Yates and Co-Founder Dr. Maciej Trzaskowski met with close to 100 investors and industry leaders to discuss Ketim’s biomarker validation progress, regulatory pathway, and commercialisation strategy for its predictive blood-based diagnostic for postpartum depression.

Support from the Brisbane Economic Development Agency and the Queensland delegation played a key role in facilitating introductions and strengthening Queensland’s presence on the global MedTech stage.

The week also included meetings with international collaborators and health innovation organisations exploring partnerships to address perinatal mental health through precision diagnostics.

Following RESI JPM, the team continues its North American engagement with meetings in Canada and the United States, including discussions with commercial partner Bio-Techne to advance translational and manufacturing pathways.

“Global engagement is critical as we move toward clinical validation and international market readiness,” said Dr. Yates. “The level of interest and collaboration we experienced reinforces the urgency and opportunity within precision psychiatry.”

Ketim’s participation reflects growing international momentum as the company progresses toward regulatory and commercial milestones.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au